Seventrader (@7Trader) su getquin

4Mes·

Eckert & Ziegler
$EUZ (+5,02%) significant year-on-year increase in sales and earnings in Q1. Forecast for 2024 confirmed.

1st quarter 2024:

Sales EUR 67.6 million (previous year: EUR 57.9 million)

EBIT before special items EUR 15.0 million (previous year: EUR 10.7 million)

Net profit EUR 8.5 million (previous year: EUR 4.7 million)

Forecast for 2024:

Sales of just under EUR 265 million (confirmed)

EBIT before special items of around EUR 50 million (confirmed)

What is the share price doing? It's finally going up again and has jumped 12% today.

I like it 🤑🤞🏼

5 Commenti

GeldmitKopf@cashwithhead

4Mes

I would be happy but my purchase price is just under 36 so despite 12 I am only at 2% plus😂

••

Mostra la risposta

Smudo@Smudeo

4Mes

In any case, the Berlin-based radiation specialist met expectations with its 2023 figures presented at the end of March (sales: +11% to a record EUR 246.1m; guidance: around EUR 230m; EBIT: -3% to EUR 45.5m due to higher costs). m due to higher costs) and, in our view, set itself sufficiently ambitious, margin-expanding targets for 2024 (sales: +8% to around EUR 265 m; consensus: EUR 266 m; EBIT: +10% to around EUR 50 m; consensus: EUR 54 m).

In addition, the strategic orientation, which envisages a sale of the loss-making drug development business (see PB of 31.10.23) in order to expand the driving business with radiopharmaceuticals, which achieved cross-segment sales growth of 28% to EUR 85m in 2023, is right.

However, the SDAX share price (EUR 36.94; DE0005659700) has fallen by around 10% since the beginning of the year - even though analysts have raised their profit expectations for the current year by 15%. The 2024 P/E ratio of 20 (10Y: 27) is therefore as attractive as it was at the end of 2018.

••

User03@User03

4Mes

The figures won't come for another 21 days, will they? Wasn't that just a pre announcement?

••

Mostra la risposta

Partecipa alla conversazione